PW Serruys, K Takahashi, P Chichareon… - European heart …, 2019 - academic.oup.com
Aims To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month …
Objectives The aim of this study was to compare ticagrelor monotherapy with dual- antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting …
M Ono, H Hara, H Kawashima, C Gao, R Wang… - …, 2022 - research.rug.nl
Background: The optimal antiplatelet strategy in the second year after percutaneous coronary intervention (PCI) remains unclear. Aims: We aimed to compare ticagrelor …
Importance Among patients undergoing percutaneous coronary intervention (PCI), it remains unclear whether the treatment efficacy of P2Y 12 inhibitor monotherapy after a short …
RHM Furtado, JC Nicolau, G Magnani, K Im… - European heart …, 2020 - academic.oup.com
Aims PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with …
Background Whether a regimen of ticagrelor monotherapy attenuates bleeding complications without increasing ischemic risk in patients undergoing complex …
BK Kim, SJ Hong, YH Cho, KH Yun, YH Kim, Y Suh… - Jama, 2020 - jamanetwork.com
Importance Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy …
Background The optimal duration of dual antiplatelet therapy after coronary drug‐eluting stent placement in adults with stable coronary artery disease (SCAD) versus acute coronary …